Tuesday October 5 6:53 AM ET
ZURICH (Reuters) - Ares-Serono, the listed Swiss biotechnology company, said Tuesday it began comparative testing of high- and low-dose interferon beta-1a treatments of the debilitating multiple sclerosis (MS) disease.
The so-called head-to-head trial of high-dose Rebif and low-dose Avonex should shed light on clinical evidence that suggests patients respond better to higher doses which affect the progression of MS, Ares-Serono said in a statement.
An estimated one to two million people around the world suffer from MS, which affects the central nervous system.
Ares-Serono had 1998 sales of $918 million in over 100 countries.